Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

PALO ALTO, Calif.--(BUSINESS WIRE)--Nov 8, 2022--

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the appointments of Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. to the company’s board of directors.

"We are excited and honored to welcome two well-known and respected biopharmaceutical leaders to our Board of Directors, joining us in our mission to develop novel myeloid checkpoint inhibitors for cancer patients,” said Charlene Liao, Ph.D., founder, chief executive officer and chair of Immune-Onc. "Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board. Our company and patients will benefit from their R&D leadership and perspectives."

“Immune-Onc’s pioneering role in developing myeloid checkpoint inhibitors as next generation immunotherapies has impressed me,” said Dr. Gurney. “I am excited to work with the team to advance its growing portfolio of first-in-class and potentially best-in-class molecules through research and development, and ultimately to patients.”